Let's take a look at the updated NACI recommendations for the AstraZeneca vaccine...

Thread based on Appendix E, analyzing benefits of the AstraZeneca vaccine (preventing ICU admissions & deaths from COVID) vs risks of waiting for a later mRNA vaccine: canada.ca/content/dam/ph… Screenshot of first page of the updated NACI recommendations
QUICK SUMMARY: if you're in AB or ON, or anywhere with high COVD cases, the protections the AstraZeneca vaccine offer outweigh the rare but real risks -- at any age.

Also seems true for 30+ in areas with medium COVID levels.

Note current supply & provincial eligibility criteria
IMPORTANT: I'm trained as a scientist, but in neuroscience/molecular genetics -- fields completely unrelated to this topic.

Only expertise I bring to this, besides a love of data, is based on my work as a science communicator, particularly one specialized in vaccine confidence
(PS. lots of hot takes on this right now... anyone not clearly stating the caveats to their expertise in relation to this particular multi-dimensional subject is someone whose advice you may wanna take with a grain of salt)
Now let's dig into NACI's analyses: they assumed risk of VITT (Vaccine-induced Immune Thrombotic Thrombocytopenia) = by age & gender given lack of conclusive data to suggest otherwise.

(Because it's rare, not enough cases worldwide to be sure trends aren't confounded by rollout)
The reason they stratify risks by age in their analyses is because it is clear that the likelihood of severe outcomes from COVID-19 increase with age (see Table 19).

Though that's just looking at hospitalization, ICU admission & death from COVID... not long COVID aka PASC. Table 19 from the NACI recommendations showing increased neg
What about underlying conditions? Gonna reference the brilliant Dr. @MPaiMD ...

Here she states that *based on what we know so far* there are not many underlying factors that seem to make someone at higher risk of developing VITT after AstraZeneca

They do a few different analyses, some assuming risk of VITT is 1 in 100,000 doses of AstraZeneca given, others assuming 1 in 250,000 doses.

I'll show the ones assuming 1 in 100,000 to play it safe, since that's closer to what our fave Dr. @MPaiMD says
They also assumed one dose of the AstraZeneca vaccine has an effectiveness of 80% for preventing severe COVID outcomes.

This is fair based on findings from Scottish study that it can reduce risk of hospitalization by as much as 94%.

Here are some of their other assumptions. Assumed a single dose vaccine effectiveness for the AstraZen
I don't love how NACI's statement gives the impression the AstraZeneca vax is inferior (it is equally effective at preventing hospitalizations and deaths from COVID, even with 1 dose).

But I do like how their analyses factor in the risk of each week of waiting for an mRNA vax ⤵️ Table 20 showing projected wait time to mRNA vaccines from m
If you're in Ontario or Alberta, the conclusion from all NACI risk/benefit analyses are the same: take the 1st vax you can.

Both currently in "high" category of COVID levels with >30 new daily cases per 100k.

In ON, that's ~4371 new daily cases
In AB, it's ~1311 new daily cases Graph of moving average of cases in the last 7 days in OntarGraph showing moving average of cases in the last 7 days, sh
This table convinced me AZ benefits outweigh risks for any age in ON & AB ("high" COVID level).

Grey boxes = safer to get AZ vax than wait for mRNA

Note conservative variables: VITT risk (1 in 100k doses), assumes low ICU admission rate from COVID & every case of VITT -> ICU For all age groups between 20-29 and to 60-69, more people a
NACI analyses suggest that, even if you assume the worst of VITT and decent COVID outcomes in areas with high COVID:

For 30 to 39 year olds, the AstraZeneca vaccine could prevent 2.42 ICU admissions per 100k cases

Compared to 1 per 100k vaccinated with AZ who could get VITT.
For #GenXZeneca (age 40-49), the most conservative estimates from NACI suggest 1 AstraZeneca dose can prevent the 3.09 ICU admissions per 100k in high COVID areas.

Compare to 1 in 100k risk of VITT per dose.

If you recently got the AZ vax, you can feel good about that decision!
If you're somewhere with moderate levels of COVID spread (7.5 new daily cases per 100k people): the risk vs. benefit teeters depending on variables used.

But it often still tilts in favour of those 30+ getting the AstraZeneca vaccine vs. waiting for an mRNA vaccine.
For ex, keeping VITT risk @ 1 in 100k, and using slightly higher ICU admission rate from COVID (what they say is closer to recent overall rate):

1 dose of AZ offers more protection against ICU admission from COVID for 30+ than VITT risk, even @ moderate COVID levels (grey boxes) For those 30 to 39 in areas of moderate covid spread (7.5 ca
When you factor in that VITT is treatable (4/5 cases in Canada reportedly recovering at home), and that outcomes are probably better now that we've learned more about it...

I think offering the AstraZeneca vaccine to those 30+ makes sense, even in areas with moderate COVID risk.
Internationally, regulatory agencies in UK and Europe have reached similar conclusions as NACI.

See this summary of the EMA's conclusions this week on the AstraZeneca (aka Vaxzevria) vaccine from the wonderful @kakape
While NACI hasn't made statements on the Janssen J&J vaccine yet, here's the decision on that from the US.

Note both AstraZeneca and Janssen J&J use adenovirus vector, but unclear to what extent risks & mechanisms of clots following each vax are the same.
CAVEAT: these are my interpretations of the NACI statement, as it currently stands April 24 at 2pm.

I am a scientist so I am comfortable reading and interpreting data, but this is not my area of trained expertise so I speak to you here as a communicator, not expert.
If you'd like to hear from a subject matter expert on clots, please check out this thread from the brilliant @MPaiMD.

This is a Dr. Menaka Pai stan account. She's the best (& lead author of @COVIDSciOntario's summaries on this topic, which are also great)
And here's a summary of what infectious disease expert Dr. Allison McGeer had to say about the benefits vs. risks of the AstraZeneca vaccine

(TL;DR -- if you're in Ontario or AB, take whatever vaccine you can ASAP).

For what it's worth, it is not my job to convince anyone to take any vaccine ever.

But I do see it as my job as a science communicator to make navigating the evidence to help with this decision a little easier.
And regardless where you get your info from, always good to discuss your personal health concerns with your doctor since they know the full scope of your medical history 💗
If you want to share this with people not on Twitter, I compiled everything in this thread on @Medium here:

heysciencesam.medium.com/the-protection…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with 🔬Samantha Yammine, PhD (aka Science Sam)

🔬Samantha Yammine, PhD (aka Science Sam) Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @heysciencesam

16 Apr
I asked people on Instagram what may be making them or their loved ones feel unsure about booking an appointment for an #AstraZeneca vaccine.

🧵 Thread with my 15-second answers to the 9 most frequent questions they asked.

#VaccinesWork #Canada #Ontario
Q: How effective is [the AstraZeneca vaccine] compared to other vaccines?

A: When it comes to just one dose, which is all most people in Canada are gonna have for the next few months, the mRNA vaccines have similar effectiveness to the AstraZeneca.

NACI: canada.ca/en/public-heal…
Q: My mom is hesitant b/c she has seen the [AstraZeneca] efficacy is lower than Pfizer?

A: Study out of Scotland (bmj.com/content/372/bm…) looked at effectiveness of reducing hospitalizations 1 month after just 1 dose:

Pfizer: 85% ⬇️🏥
AstraZeneca: 94% ⬇️🏥

Both #VaccinesWork.
Read 13 tweets
14 Apr
I'm reflecting a lot on Aristotle's 3 appeals for effective rhetoric.

In part b/c of the news about the very rare & atypical clots after AstraZeneca & now Janssen J&J vaccination... but also just with how we talk about the science of the pandemic in general.

#SciComm 🧵 | 1/13
I know many argue rhetoric - or persuasive communication - has no place in science, and I agree my goal is never to persuade but to inform.

But we always have to make our arguments "appealing", even those based on facts.

To catch attention, & make em relatable/memorable.

2/13
We can debate the role of rhetoric in science communication later, but for now, the three appeals are:

✨LOGOS - logic
✨PATHOS - emotion
✨ETHOS - character/credibility

3/13
Read 13 tweets
12 Apr
A friendly reminder to always approach the topic of vaccinations with empathy. Hesitancy is complex & has many layers.

ie. this week, I've been receiving a lot of msgs from people scheduled for 1st or 2nd AstraZeneca vax. They want a vaccine but are SO anxious from the news 😔
Anxiety is also high in those who recently received their 1st dose & are now seeing headlines that have them on edge.

I am glad the potential rare side effect of clots has been so transparently shared by experts & media.

But all the more reason to be kind in our scicomm 💕
I've had anxiety forever (in the midst of finding a new therapist now!🎉), so I feel each one of these messages in my core.

This pandemic really sucks.

I hope through empathetic scicomm with culture + trauma-informed approaches to hesitancy we can end it sooner.
Read 4 tweets
15 Sep 20
🧵

People in their 20s are now disproportionately represented in new COVID-19 cases in Ontario.

Instead of shaming & blaming, I asked them what challenges they’re currently facing with respect to the pandemic.

After 100s of replies, some key themes emerged. Here they are:
Many people in their 20s mentioned peer and social pressure, plus general difficulty navigating behaviours of those around them as a major challenge during the pandemic.
Difficulty seeing or isolating from family was cited as a key challenge folks in their 20s are facing.

This one is big given data from France suggesting cases in young people eventually spread to older folks in 3-5 weeks.
Read 13 tweets
16 May 20
A quick visual guide to risk assessment, based off some of the fantastic research summaries created by @mugecevik @firefoxx66 and @ErinBromage

1/13 Graphic saying covid-19 exposure risk = viral dose x time
Your exposure risk is some function of viral dose & time.

The tricky thing is we don’t know how many virus particles it takes to cause an infection, and this will likely vary from person to person.

The good news is we know some ways to reduce our relative risks

2/13 Graphic saying We don’t yet know how many virus particles it takes to cause an infection, but we do know how to reduce the chances of virus particles getting near our eyes nose and mouth. Yes physical distancing and hand hygiene, but wait there’s more!
Time is perhaps an under-appreciated component of the risk equation.

Slow & steady can “win the race” to an infection too.

3/13 Time complicates things. Even exposure to a low viral dose for a long time can become risky. The more we understand the risks in our environments, the better we can get at navigating them - for the sake of everyone!
Read 14 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!